Australia markets closed

Halozyme Therapeutics, Inc. (HALO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
38.57+0.11 (+0.29%)
At close: 04:00PM EDT
37.13 -1.44 (-3.73%)
After hours: 07:49PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
829,253
829,253
660,116
443,310
267,594
Cost of revenue
192,361
192,361
139,304
81,413
43,367
Gross profit
636,892
636,892
520,812
361,897
224,227
Operating expenses
Research development
76,363
76,363
66,607
35,672
34,236
Selling general and administrative
149,182
149,182
143,526
50,323
45,736
Total operating expenses
299,318
299,318
253,281
85,995
79,972
Operating income or loss
337,574
337,574
267,531
275,902
144,255
Interest expense
18,762
18,762
16,947
7,526
20,378
Total other income/expenses net
29,517
29,517
-1,666
-19,858
5,425
Income before tax
348,329
348,329
248,918
248,518
129,302
Income tax expense
66,735
66,735
46,789
-154,192
217
Income from continuing operations
281,594
281,594
202,129
402,710
129,085
Net income
281,594
281,594
202,129
402,710
129,085
Net income available to common shareholders
281,594
281,594
202,129
402,710
129,085
Basic EPS
1.91
-
1.48
2.86
0.95
Diluted EPS
1.87
-
1.44
2.74
0.91
Basic average shares
133,489
-
136,844
140,646
136,206
Diluted average shares
136,269
-
140,608
146,796
141,463